BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 157 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $472,632 | +0.6% | 66,756 | 0.0% | 0.09% | -2.1% |
Q2 2023 | $469,962 | -16.8% | 66,756 | -1.5% | 0.10% | -18.8% |
Q1 2023 | $565,085 | -27.0% | 67,756 | +0.5% | 0.12% | -28.7% |
Q4 2022 | $773,637 | -8.9% | 67,390 | 0.0% | 0.16% | -23.0% |
Q3 2022 | $849,000 | +19.6% | 67,390 | +0.5% | 0.21% | +27.5% |
Q2 2022 | $710,000 | -60.0% | 67,088 | -38.6% | 0.17% | -52.3% |
Q1 2022 | $1,775,000 | +17.4% | 109,188 | 0.0% | 0.35% | +23.7% |
Q4 2021 | $1,512,000 | -3.6% | 109,188 | 0.0% | 0.28% | -12.1% |
Q3 2021 | $1,569,000 | -11.2% | 109,188 | -2.2% | 0.32% | -11.0% |
Q2 2021 | $1,766,000 | +42.8% | 111,678 | -8.2% | 0.36% | +35.6% |
Q1 2021 | $1,237,000 | +57.8% | 121,678 | +15.7% | 0.27% | +37.6% |
Q4 2020 | $784,000 | – | 105,178 | +15.4% | 0.19% | – |
Q3 2020 | $0 | -100.0% | 91,178 | +10.3% | 0.00% | -100.0% |
Q2 2020 | $394,000 | +126.4% | 82,678 | -5.1% | 0.12% | +88.7% |
Q1 2020 | $174,000 | +58.2% | 87,078 | +172.1% | 0.06% | +93.8% |
Q4 2019 | $110,000 | – | 32,000 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |